Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of SHR-8068 vs Ipilimumab in Healthy Chinese Men
NCT07852325Phase 1Completed
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Jan 2024
- Primary completion
- Dec 2024
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CS1002 in melanoma (2 arms), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoints: Maximum Serum Concentration at Day 57 and Area Under the Serum Concentration-Time Curve From Time Zero Extrapolated to Infinity at Day 57. Started Jan 2024; status: completed.
02
Drugs
CS1002
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT07852325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07852325.